• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Endo Agrees to Buy Par Pharmaceutical for $8 Billion


May 18, 2015.

Dublin-based Endo International has agreed to buy Par Pharmaceutical Inc. (Chestnut ridgem, NY) from private-equity firm TPG for about $8 billion, the Wall Street Journal reported today.

Par has a portfolio of nearly 100 products; the acquisition will push Endo's generics business into the top five by U.S. sales.

The Par acquisition is the latest in an Endo buying spree. In January, the company closed its $2.6 billion purchase of Auxilium Pharmaceuticals; before that it added Boca Pharmacal and DAVA Pharmaceuticals to its generics operations. 

Related Videos